A example of how different targeted therapy and immunotherapy combinations could be both useful and different from what we've seen before
Juno ROCKET trial put on clinical hold following 3 death due to cerebral edema. What's the skinny?
Will priming the tumour microenvironment with epigenetic therapies such as HDACs lead to enhanced activity with subsequent immunotherapy?
With so many new anti-cancer agents, including immunotherapies, emerging in company pipelines, this means that we could see the evolution of important therapy sequences... going beyond combinations.
The oncology bispecific market is heating up with J&J collaborating with Macrogenics and Novartis with Xencor. We discuss the skinny...
We've seen some wonderful responses with checkpoint blockade and cancer immunotherapies, but there are some downsides that need to be considered.
Can we turn a cold tumour into a hot one where some patients can respond to therapy?
Update on ASCO checkpoint blockade data for colorectal and other MSI-High cancers
An easy to use new biomarker emerges to help oncologists select colon cancer patients for cancer immunotherapies.
Gene editing is coming to the US CAR T cell space - what's happening and what will the impact be?
Can we find and use several biomarkers to triangulate responders and non-responders?
A look at the increasingly competitive metastatic urothelial carcinoma landscape
What to make of the various combination trials presented at ASCO 2016?
A number of points of strategic importance fell out of the ASCO data dump. What are they and why do they matter?
Commentary from Monday at ASCO 2016 American Society of Clinical Oncology annual meeting in Chicago
When Big Pharma turns into Bad Pharma...
Top-line commentary from Sunday at ASCO 2016 annual meeting.
Top-line commentary from Saturday at ASCO 2016 annual meeting.
Can we safely combine a STING agonist with a checkpoint inhibitor to generate more effectiveness in melanoma and lymphomas?
We asked experts at AACR what they really thought...
What can we learn about clinical trial design from immunotherapy combinations?
Commentary from the AACR Precision Medicine Conference in Miami on Targeting the Vulnerabilities of Cancer.
How can we improve T cell trafficking in ovarian cancer? Professor Coukos highlights numerous ways this could be achieved!
A look at the BCMA/APRIL landscape in multiple myeloma - this is rapidly becoming a competitive target
Beyond checkpoint blockade, companies are now exploring what happens when you combine them with immune agonists such as OX40. Here we explore an industry perspective.
A wide ranging discussion about how to light the fires in non-immunogenic or cold tumours - OX40, STING, vaccines and more discussed!
Can we safely and effectively add a checkpoint inhibitor to standard chemotherapy and VEGF inhibition?
Early proof of concept in patients with metastatic colorectal cancer.
At the recent AACR meeting, Dr Michel Sadelain gave a presentation on turbocharged CAR T cells, and shared some of his ideas on how to move the field forward.
Chemotherapy can have a potentiating effect on cancer immunotherapy. The positive effects may surprise some readers...
What were the major learning points from AACR that will make an impact over the next 1-2 years? Chhhhanges are afoot...
Season 2 of the Novel Targets has launched, plus the eagerly awaited April Readers Q&A Mailbag
Commentary on Tuesday sessions at AACR 2016 annual meeting
Commentary on Monday at AACR 2016 annual meeting
Commentary from Sunday at 2016 AACR annual meeting
Commentary on Day 1 of AACR 2016 annual meeting in New Orleans.
First-line data for AstraZeneca’s ($AZN) third generation EGFR inhibitor osimertinib (Tagrisso) impresses at the 2016 European Lung Cancer Conference in Geneva.
In this preview of AACR 2016, we're looking at the CD40 landscape, some of the new companies that have entered the scene and what presentations to look out for at AACR 2016 (and why they matter).
Today post is on OX40 (CD134) as a novel immuno-target and what the OX40 cancer immunotherapy landscape looks like.
There are now several agonist antibodies in development and entering the clinic that seek to activate GITR, and new data is expected at AACR 2016.
This post looks at some of the data at AACR 2016 for cancer immunotherapies that target IDO1 and TDO and their downstream effectors.
A look at alternative checkpoint inhibitors, anti-TIM-3 and LAG-3 compounds in early development at AACR
In this post I've taken a close look at one cancer immunotherapy approach with a lot of data at AACR - bispecific T cell engagers.
Commentary on some of the latest cancer immunotherapy papers
Pick of 10 abstracts at AACR 2016 annual meeting in New Orleans that may answer critical cancer research questions
Cancer Immunotherapy dominates AACR 2016 annual meeting in New Orleans.
Review of 4 noteworthy posters at the 2016 European Breast Cancer Conference in Amsterdam organised by European Cancer Organisation ECCO
Trends in Haplo stem cell transplants may impact Bellicum Pharmaceuticals adjunct T Cell therapy BPX–501
Could immune resistance be reversed or prevented by the addition of appropriate checkpoint blockade? Which ones matter though, that is the critical question?
Interview at BMT Tandem 2016 about a novel cell therapy that could compete with or replace CAR T cell therapy
Commentary on presentation by Dr Philippe Armand at BMT Tandem meeting on “Checkpoint Blockade in SCT, Data & Hope, Promise & Peril”
Interview with Dr Michael Jensen on CD19 CAR T Cell Therapy
Interview at BMT Tandem 2016 with Dr David Porter U Penn on CD19 targeted CAR T cell therapy in CLL
Preview of noteworthy sessions at 2016 BMT Tandem meeting in Honolulu, Hawaii
What are some of the strategic trends and drivers in the Graft versus Host Disease (GvHD) space at #BMTTandem16?
Unum have developed a completely different approach to traditional CAR T cell therapies. Will they make an impact in patients?
A novel cell therapy approach uses T cells targeting multiple tumor-associated antigens.
Who will move the needle in gastric and oesophageal cancers - targeted therapies or checkpoint immunoherapies?
Will checkpoint blockade be effective in multiple GI cancers and if so, why?
A trial of gemcitabine plus cisplatin plus ipilimumab in patients with metastatic urothelial cancer failed to meet it's primary endpoint.
Commentary on Wednesday corporate presentations at 2016 JP Morgan Healthcare conference in San Francisco
Commentary on some of the presentations at Day 2 of JP Morgan Healthcare conference in San Francisco.
Commentary around some of the corporate presentations at Day 1 of the 2016 JP Morgan Healthcare conference in San Francisco.
ASH 2015 interview with Dr Ian Flinn, Director of the Blood Cancer Research Program at the Sarah Cannon Research Institute.
Part 2 of ASH 2015 interview with Prof Waseem Qasim (GOSH) on the first in man gene edited allogeneic CAR T cell therapy.
Part 1 of an interview with Prof Waseem Qasim.
Adding chemotherapy or an ADC boosts the immunogenic effects prior to checkpoint therapy in metastatic breast cancers
Commentary on Plenary Sunday at the 2015 ASH annual meeting in Orlando.
Commentary on Saturday at ASH15
Where is the field of immune biomarkers going beyond PD-L1 in the next few years?
Checkpoints in classical Hodgkins Lymphoma - how is the data holding up one year on?
At the recent Society for Immunotherapy of Cancer (SITC) annual meeting, Dr Chris Heery presented a poster on the results of a phase 1 clinical trial to evaluate the safety and tolerability of a therapeutic vaccine targeting brachyury.
Our latest Q&A based on reader questions - In the Hot Spot: On CAR T cell therapies
Interview with Dr Mario Sznol on Novel Immunotherapies and Combinations
Dr Tom Gajewski (University of Chicago) talks about work from his lab that shows the gut microbiota can impact the efficacy of checkpoint inhibitors.
Interview with a leading expert on strategies to overcome CAR T Cell Therapy Resistance
At SITC 2015, we heard a tremendous amount of data, but a fresh controversy emerged regarding checkpoint inhibition...
Expert opinion on First Clinical Application of TALEN Engineered Universal CAR19 T Cells in B-ALL
Enoblituzumab is an immune stimulant that targets B7-H3 leading to more T cells.
Is Incyte's epacadostat (IDO1 inhibitor) ready for prime time?
Review of the highlights from the SITC 2015 pre-meeting workshops
Most of the abstracts for the 2015 annual meeting of the American Society of Hematology (ASH) have just gone online.
This is a quick initial preview of a few that caught my attention in the immunotherapy space.
Commentary on the International Cancer Immunotherapy Symposium held at SITC 2015
Preview of what's hot at the 2015 Society for Immunotherapy of Cancer (SITC) annual meeting at National Harbor, MD.
Companies in the ImmunoOncology space are looking at ways to improve responses with checkpoint inhibitors. Adding an immune agonist is one way to do this.
A primer on immunocytokines in cancer immunotherapy with a focus on Roche's CEA-IL2v as a example.
Interview with Dr Jérôme Galon on Immunosurveillance, Immunoscore and Personalized Cancer Immunotherapy.
Preview of the key topics coming up at the AACR-NCI-EORTC Molecular Targets meeting in Boston, including Pasi Janne's interesting data on T790M negative NSCLC...
Should we be using the PDL1 antibody assay to screen patients for therapy with anti-PD1 and PD-L1 checkpoint inhibitors or? How useful is the test?
The debate is heating up!
Radiation has the potential to generate an immune response that may lead to an abscopal effect when combined with a checkpoint inhibitor.
Will an increase in ILD cases scupper the AZD9291 plus durvalumab combination study in lung cancer? Will there be an advantage for Clovis or not?
Interview at ECC 2015 with Dr George Demetri on new developments in Soft Tissue Sarcoma
Interview with Dr Nora Disis about the phase 1b trial results for avelumab in ovarian cancer and the challenges of developing these agents in non-hypermutated tumour types
Commentary on Day 3 of the European Cancer Congress in Vienna
Commentary on Day 2 of the European Cancer Congress in Vienna
Highlights from Day 1 of the ECC 2015 (ECCO) meeting in Vienna
What happens when we literally step on the gas with immune agonists?
T cell immunoglobulin and mucin domain-containing molecule-3 (TIM-3) is widely expressed on immune cells. What's the potential for a TIM-3 checkpoint inhibitor?
Review of noteworthy abstracts at CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference in New York
Holbrook Kohrt is a Stanford medical oncologist and clinical researcher who is leading the way in cancer immunotherapy combination strategies targeting CD137 (4-1BB).
Immunocore is an immuno-oncology company with an innovative approach to targeting T Cell Receptors (TCR) using their proprietary ImmTAC (Immune mobilising monoclonal TCRs against cancer) technology platform.
What's hot at ECCO 2015 in the oral sessions? An in-depth preview of what we can expect to hear about in Vienna...
What's hot in the 2015 ECCO late breaking abstracts in Vienna? Find out here...
Atezolizumab is expected to change the standard of care for the treatment of metastatic urothelial bladder cancer
Dr Carl June on progress of CAR T cell therapies in CLL, myeloma and solid tumours
We know that TILs can be effective in advanced melanoma, but what about common epithelial solid tumours? Can it work in these cancers too? Find out from Dr Rosenberg's latest work what's happening...
Oncolytic viruses are fast becoming a hot new area in cancer research but who are the players and where is this field going?
Exploring NY-ESO-1 as a valid target in sarcoma, multiple myeloma and metastatic melanoma...
Will checkpoint inhibitors make their mark in renal cell carcinoma and how will they be integrated into a treatment paradigm dominated by VEGF inhibitors?
Can we find new ways to target prostate cancer and other non-immunogenic tumours with immunotherapies? The answer may surprise...
Interview with Dr Rob Iannone of AstraZeneca on their IO pipeline
Interview with Dr William Pao on the Roche antibody based cancer immunotherapy strategy.
Editas presented some elegant work using their gene editing technology with CRISPR/Cas9 to modify T cells at ASGCT. Who would have guessed a short time afterwards Juno and Celgene would sign a 10 year collaboration?
ASCO 2015 interview with Dr James Gulley from NCI on Prostate Cancer Immunotherapy.
We've heard a lot about checkpoint immunotherapies in non-small cell lung cancer (NSCLC), but what about it's deadlier cousin, small cell lung cancer (SCLC)? Find out more...
Beyond the Big Four in checkpoint inhibitors, there is a raft of other companies anxious to get in the action. We take a look at Merck Serono and their progress with avelumab, an anti-PDL1 antibody
How do we help patients who are non-responders or have stable disease respond to checkpoint inhibitors? Will chemotherapy combos help or not?
Highlights from Monday at the 2015 ASCO annual meeting in Chicago
What's hot on Plenary Sunday at ASCO 2015? We'll be updating this blog post during the day.
Highlights from Day 2 at ASCO 15 in Chicago
Reflections on data presented in the first cancer immunotherapy press briefing at ASCO 2015
Do you need to incorporate a suicide suicide switch into CAR T cells that allows you to turn off the response, force the T cells to self-destruct?
Data at ASGCT and ASCO highlight potential new treatments in development for multiple myeloma
Update on checkpoint inhibitors in urothelial bladder cancer from AUA 2015 and what's in store for new developments with this disease.
First in a series of previews of ASCO 2015 annual meeting abstracts.
Dr Tom Gajewski is working on STING agonists that may have a major role to play in cancer immunotherapy.
At the 2015 annual meeting of the American Association of Immunologists (AAI) in New Orleans, leading experts shared their insights on the “Promise of Cancer Immunotherapy."
What are the hot checkpoint studies to watch out for at ASCO 2015? We created a cheat sheet to follow and track the data as tsunami hits...
What happens when we combine a checkpoint with an immune stimulant in advanced melanoma?
Beyond monotherapy with checkpoint inhibition, what combinations or sequences might be useful to explore next?
Beyond lung cancer and melanoma, what other tumour types represent the low hanging fruit for checkpoint monotherapy?
As the anti-PD-1 blockers show superiority in front-line metastatic melanoma, is this the end for Yervoy?
The annual meeting of the American Association for Cancer Research ended today. Find out what were our top 10 highlights.
Checkpoint Inhibitor data is a hot topic at AACR 2015. Data showed they may work in TNBC and also two checkpoints are better than one.
Cancer Immunotherapy is one of the hot topics at the 2015 AACR annual meeting in Philadelphia.
Does checkpoint blockade with CTLA4 have a role to play in hematologic malignancies?
University College London (UCL) is leading the way in European clinical trials of CAR T Cell therapies that target CD19.
Emerging data on different combinations with checkpoint inhibitors suggests that this may increase response rates and outcomes for cancer patients. Find out more...
Novartis have announced a deal with Aduro Biotech for access to their STING-targeted CDN platform technology.
The mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Novel targets are emerging in urothelial bladder cancer which may offer new therapeutic options for antibody and CAR-T cell therapy development.
Why is renal cell carcinoma so challenging from a clinical and sequencing perspective?
What is the potential of a new cell therapy with cytotoxic T lymphocytes against Epstein Barr Virus (EBV-CTL)?
Predictive biomarkers of response will be key to reimbursement of immunotherapies in Europe. One is potentially emerging for ipilimumab (Yervoy), which may be useful in speeding up access.
What are the emerging new trends in cancer immunotherapy? Beyond monotherapy lies many combination opportunities yet to be explored. At AACR in April, we will see a raft of novel approaches being discussed.
Will checkpoint inhibitors make an impact in hematologic malignancies or will novel combinations be needed?
Not all cancers respond to checkpoint inhibitors - how can we change that situation? Here's one example, using prostate cancer as a model...
Dr Krishna Komanduri discusses some of the best abstracts at the 2015 BMT Tandem meeting in San Diego.
Cellular Biomedicine Group (NASDAQ: CBMG) has acquired rights to the Chimeric Antigen Receptor T cell (CAR-T) therapy of the PLA General Hospital in Beijing.
What does the evolving landscape for CAR, TIL and TCR cell therapies look like?
The NCI have been at the forefront of developing novel cancer immunotherapies for several decades, but what is the current status of their groundbreaking work? Find out more in this primer on TILs.
What's the vision for Bellicum Pharmaceuticals? In an in-depth interview CEO Tom Farrell and COO Annemarie Moseley discuss the benefits offered by their new products in development.
What's next in immuno-oncology: what are potential ways to tackle the patients who do not respond to checkpoint immunotherapy?
What makes the Cellectis Chimeric Antigen Receptor CAR-T cell therapy different and what are the milestones expected in 2015?
Graft versus Host disease (GvHD) is an area of tremendous unmet medical need that is triggering the interest of a number of biotech and rare disease companies.
There is a lot of interest in checkpoint inhibitors, do they look they will be effective in Triple Negative Breast Cancer?
"Manic Monday" at the annual meeting of the American Society of Hematology features multiple oral sessions run at the same time!
Coverage of Day 2 of the annual meeting of the American Society of Hematology in San Francisco.
It's Day 1 of the 2014 annual meeting of the American Society of Hematology meeting in San Francisco.
ASH 2014 Multiple Myeloma data looks like it offers much promise for new treatments as well as an increasingly competitive marketplace
The science of targeting PD-1 and it's ligand PD-L1 in cancer immunotherapy is highlighted in five Letters published in Nature this week.
How can we jumpstart the immune system to enable more patients to respond? At SITC we learned more about targeting CD40 to achieve this.
At the SITC 2014 annual meeting, Dr van den Brink presented data on how the bacteria in our gut (the intestinal microbiome) can impact GvHD.
At the Society for Immunotherapy of Cancer (SITC) meeting last week, one of the Hot Topic sessions that took place after the conference formally ended was in managing the toxicities associated with chimeric antigen receptor T cell (CAR-T) therapy.
OX40 could be an exciting new target in immune-oncology that could be combined with checkpoint inhibitors to improve the T cell response.
Reflections on Day 1 of the 2014 annual meeting of the Society for Immunotherapy of Cancer (SITC).
Day 1 of the SITC annual meeting started with two workshops on immunotherapy and combination therapy
This week sees the start of the 2014 annual meeting of the Society for Immunotherapy of Cancer (SITC) at National Harbor, MD.
We’re excited to be attending this meeting for the first time.
There was a lot going on in lung, melanoma, renal and colorectal cancer in terms of immunotherapy in Madrid.
Merck announced their Breakthrough therapy designation for Keytruda in lung cancer this morning. What did we learn from the updated data for checkpoint inhibitors in NSCLC at ESMO that was different from ASCO?
Checkpoint inhibitors are looking very promising in advanced gastric cancer
At ESMO 2014, phase 1 clinical trial data in bladder cancer was presented for Pembrolizumab (Merck) and MPDL3280A (Roche/Genentech).
Genentech and NewLink announced a deal to license an IDO inhibitor. What's the impact of this on the IO pipeline?
Day 3 of the live blog from the ESMO 2014 Cancer Congress in Madrid.
Day 2 Live Blog with news and commentary on what's taking place at the ESMO Cancer Congress in Madrid
ESMO 2014 Cancer Congress data starts to roll out today - throughout the day we'll be updating the blog with initial impressions of data as it's presented.
Most of the abstracts for oral presentations at the forthcoming ESMO cancer congress in Madrid have just been released. This is a preview of some that caught my attention.
There are some interesting science symposia at #ESMO14 in both immunotherapy and targeted therapies. We review what the hot topics are here.
A review of the key poster and poster discussion abstracts on immunotherapy and targeted therapies at ESMO 2014
Update on what to watch out for in immunotherapy at ESMO 2014.
How will we decide which therapies to give patients with metastatic melanoma once the new immunotherapies are available?
Cellectis is a Paris based biotechnology company with a “blue ocean” strategy that, if successful, could revolutionize cancer immunotherapy.
After it's successful IPO, what are some of the challenges and opportunities facing Kite Pharma and their CAR-T cell immunotherapy?
AstraZeneca showed impressive data at ASCO 2014 for MEDI4736, a new anti PD-L1 immunotherapy.
There have been no new therapies in urothelial bladder cancer for 30 years - until now...
PD-1 antibodies nivolumab and pembrolizumab show considerable promise in metastatic melanoma. At ASCO 2014 we learnt more about how they compare against each other and their potential as a backbone for combinations.
What does the ASCO 2014 data show when you combine checkpoint inhibitors nivolumab and ipilimumab?
Insights on checkpoint inhibitors, co-stimulants, CAR T cell therapy and bispecific antibody TCRs
Update on emerging potential immuno-oncology biomarkers and combinations from AACR
This weekend at AACR a controversy emerged on the safety of Juno's CAR T cell therapy.
A review of innate immunotherapies including CD47, KIR, MICA and anti-glucan data at AACR in San Diego.
Much has been written about CAR T cells in B cell leukemias, but what about B cell lymphomas? Kite and the NCI had the honour of being the first to present data from ASH on their therapy in refractory DLBCL lymphomas
ASCO GU saw an update on the ipilimumab study in post chemotherapy CRPC. New biomarker data published this week in melanoma may be potentially useful in prostate and other tumour types.
Update on progress with anti-PD1 and PD-L1 immunotherapies in renal cell cancer. Where is the field going in this space?
Roche Genentech are developing their anti-PD-L1 as both monotherapy and also in combination with targeted therapies in lung, melanoma, renal and colon cancers. How is the early development progressing?
“We are at beginning of a REVOLUTION in immunotherapy,” said Elizabeth M. Jaffee, MD at the start of American Society of Clinical Oncology GastroIntestinal (ASCO GI) symposium keynote lecture on Immunologic Treatments for GI Cancers.
UPenn and CHOP are using genetically modified chimeric antigen receptor (CAR) T cells to treat patients with B cell cancers such as ALL, B cell NHL, CLL and other B cell malignancies.
At ASH, the impressive data from adult and pediatric ALL was presented.
This post includes insights on this approach and an interview with Dr Stephan Grupp on the pediatric data.
Immunotherapy continues to be a hot topic in oncology with anti-PD-1 and other new approaches being discussed at the AACR-IASLC meeting in San Diego
Start-up Juno Therapeutics is now in control of a legal dispute between St Jude Children’s Hospital and the University of Pennsylvania over chimeric antigen receptor (CAR) T cells intellectual property that contributed to the development of CTL019 licensed by Penn to Novartis. Penn are seeking to invalidate a St Jude patent that if upheld, CTL019 may infringe.
Juno Therapeutics is a start-up company with a mission to revolutionize the treatment of blood cancers through the use of chimeric antigen receptor (CAR) modified T cell therapy. The company recently launched with $120 million of series A funding. One of the scientific founders is Renier Brentjens MD, PhD, the Director of Cell Therapeutics at the Memorial Sloan-Kettering Cancer Center in NYC. He kindly gave an interview while at the ASH annual meeting in New Orleans.
Immuno-oncology is a hot topic at the moment and many new targets are emerging that may be useful in combination. This post discusses Innate Pharma's anti-KIR program in hematologic malignancies.
Chimeric Antigen Receptor T cell technology (CART) is an exciting new area, especially in hematologic malignancies. With the formation of a new start-up in Seattle, Juno Therapeutics, things just got very interesting...
An update on checkpoint inhibitors and CART from the AACR-NCI-EORTC Molecular Targets meeting - a lot of exciting possibilities are emerging!
Update on ALK (alectinib), PD-L1 (MEDI4736), PI3K (GDC-0980 and BKM120) and MEK (trametinib) inhibitors in solid tumours
A quick review of the check point immunotherapy abstracts from #ECC2013 in Amsterdam.
Overview of anti-PD-1 and PD-L1 immunotherapies plus ASCO 2013 data in melanoma and lung cancer.
For many attendees, the most exciting news at the 2012 annual meeting of the American Society of Hematology (ASH) held last December in Atlanta was the prospect of personalized T cell therapy for the treatment of patients with B cell cancers such as chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL).